Key statistics
On Wednesday, Molecular Partners AG (MLLCF:PKL) closed at 2.25, 0.00% above its 52-week low of 2.25, set on Jan 28, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 2.25 |
|---|---|
| High | 2.25 |
| Low | 2.25 |
| Bid | -- |
| Offer | -- |
| Previous close | 2.25 |
| Average volume | -- |
|---|---|
| Shares outstanding | 40.37m |
| Free float | 37.02m |
| P/E (TTM) | -- |
| Market cap | 142.32m CHF |
| EPS (TTM) | -1.63 CHF |
Data delayed at least 15 minutes, as of Jan 28 2026 14:32 GMT.
More ▼
Announcements
- Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026
- Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference
- Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference
- Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics
- Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting
- Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action
- Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025
- Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting
- Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025
- Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025
More ▼
